Moreover, in sporadic MTC RAS point mutations occur in about 25% of cases and they are mutually exclusive with RET. So far, RAS is the only RET alternative driver oncogene in sporadic MTC and 20–25% of these tumors are still “orphan” of driver mutations despite the deep analysis recently performed with either targeted next-generation sequencing (NGS) or with whole-genome sequencing (WGS) [4,5,6,7]. The gene discussed is RET; the disease is medullary thyroid gland carcinoma.